Compare Celestica Inc (CLS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celestica Inc vs Smith & Nephew plc — how do they compare? Celestica Inc trades at $335.22 (market cap $39.16B), while Smith & Nephew plc trades at $29.82 (market cap $12.54B). The key difference: Celestica Inc is far larger — about 3.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Celestica Inc pays none. Which is the better fit depends on your goals.
| CLS | SNN | |
|---|---|---|
Market Cap | $39.16B | $12.54B |
Sector | Technology | Health |
52-Week High | $472.40 | $38.70 |
52-Week Low | $181.34 | $28.73 |
Enterprise Value | $39.44B | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLS trades at $336.97, up 7.11% on the day, with a bearish technical signal from moving averages but strong fundamental performance. The company reported three consecutive quarterly EPS beats, with Q2 2026 actual EPS of $2.54 exceeding the $2.29 estimate. Revenue for 2025 was $12.39 billion, with a net income margin of 7.16% and robust ROE of 52.69%. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, alongside new contracts with key tech partners.
The outlook is supported by accelerating AI-driven demand and raised guidance, but near-term dilution from the equity raise poses a risk. Analyst consensus is strongly bullish with a $466.50 price target, though the stock's premium valuation requires careful monitoring of execution against growth expectations.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
